Investing.com — Shares of Blueprint Medicines (NASDAQ:BPMC) Corporation (NASDAQ:BPMC) climbed 17% as the company outlined its growth strategy for 2025, highlighting the potential of its systemic mastocytosis (SM) franchise and positive trial data for its new treatment, BLU-808.
Blueprint Medicines, based in Cambridge, Massachusetts, updated its peak revenue estimate for its SM franchise to $4 billion, driven by the successful launch of AYVAKIT (avapritinib) and revised prevalence estimates for SM. The company now aims to achieve $2 billion in annual revenues from AYVAKIT by 2030, a significant increase from its previous guidance.
The company’s shares rose following the announcement of results from a Phase 1 healthy volunteer study of BLU-808, which demonstrated a wide therapeutic window with rapid, robust, and sustained tryptase reductions exceeding 80%. These results support the potential of BLU-808 as a best-in-class treatment for a range of mast cell-driven diseases.
Blueprint Medicines CEO Kate Haviland commented on the company’s strong positioning, citing a number of commercial and clinical catalysts expected to deliver value to both patients and shareholders. The company’s integrated approach from research to commercialization is anticipated to drive operational efficiencies and a durable financial profile.
The company previously projected AYVAKIT product revenue of $475 to $480 million for the full year of 2024, representing a growth of more than 130% over 2023. The financial results for the fourth quarter and full-year 2024 are set to be reported in February 2025.
In addition to the SM franchise, Blueprint Medicines is focusing on advancing its pipeline, including the initiation of the Phase 3 HARBOR trial of elenestinib for indolent systemic mastocytosis and prioritizing investment in CDK targeted protein degraders for breast cancer and other solid tumors.
Stifel analyst Bradley Canino provided a positive outlook on the company’s prospects: “Outlook reinforces a bull thesis that the stock provides a positive risk/reward on a dual thesis.” The updated sales projections for AYVAKIT and the promising BLU-808 trial data are expected to be key drivers of Blueprint Medicines’ growth and investor confidence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
